Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects

被引：0
|
作者：
Jing Wang
Zhi-Yi Zhang
Sharon Lu
Dan Powers
Vikram Kansra
Xiaodong Wang
机构：
[1] TESARO,
[2] Inc.,undefined
来源：
Supportive Care in Cancer | 2019年 / 27卷
关键词：
Rolapitant; Antiemetics; Neurokinin-1 receptor antagonist; Drug interactions; Cytochrome P450;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：819 / 827
页数：8
相关论文
共 50 条
  • [21] Relationship of CYP2C9, CYP2C19 and CYP2D6 genotype with functional activity in vitro.
    Pearce, RE
    Gaedigk, A
    Madan, A
    Parkinson, A
    Leeder, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P69 - P69
  • [22] Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A
    Von Moltke, LL
    Greenblatt, DJ
    Grassi, JM
    Granda, BW
    Venkatakrishnan, K
    Schmider, J
    Harmatz, JS
    Shader, RI
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1998, 50 (09) : 997 - 1004
  • [23] Relevance of CYP2C9, CYP2C19, CYP2B6 and GSTA1 polymorphisms on cyclophosphamide kinetics
    Timm, R
    Kaiser, R
    Sezer, O
    Weisz, K
    Roots, I
    Cascorbi, I
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 : R149 - R149
  • [24] Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans
    Krulikas, Linas
    Bates, Jill
    Chanfreau, Catherine
    Coleman, Heather
    Dalton, Shawn
    Voora, Deepak
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (02) : 390 - 396
  • [25] Effect of rivoceranib administered as 200 mg once daily on the pharmacokinetics of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 substrates
    Jang, Seong
    Wei, Xiaohui
    Meng, Xianzhang
    Reitano, Joseph
    Urity, Vinoo
    Park, Cheol Hee
    Strickland, Bill
    Lee, Grace
    Nguyen, David
    CANCER RESEARCH, 2024, 84 (07)
  • [26] Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
    Crettol, S
    Déglon, JJ
    Besson, J
    Croquette-Krokkar, M
    Gothuey, I
    Hämmig, R
    Monnat, M
    Hüttemann, H
    Baumann, P
    Eap, CB
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (06) : 593 - 604
  • [27] COMPARISON OF THE EFFECT OF CHRONIC KIDNEY DISEASE (CKD) ON PHARMACOKINETICS OF CYP1A2, CYP2C8, CYP2C9 AND CYP2C19 SUBSTRATES
    Tan, M-L
    Yoshida, K.
    Zhao, P.
    Zhang, L.
    Galetin, A.
    Huang, S-M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S10 - S11
  • [28] VARIABILITY IN SERTRALINE PHARMACOKINETICS EXPLAINED BY CYP2C19 AND CYP2B6
    Ramsey, Laura B.
    Poweleit, Ethan A.
    Vaughn, Samuel
    Momper, Jeremiah
    Desta, Zeruesenay
    Strawn, Jeffrey Robert
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2024, 63 (10): : S194 - S194
  • [29] SIMULTANEOUS EVALUATION OF CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP1A2 HYDROXYLATION CAPACITY IN HUMANS
    De Andres, F.
    Paulmichl, M.
    Llerena, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S61 - S61
  • [30] Determination of CYP2D6, CYP2C9 and CYP2C19 genotypes with Tag-It™ mutation detection assays
    Melis, Roberto
    Lyon, Elaine
    McMillin, Gwendolyn A.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2006, 6 (06) : 811 - 820
12345